PETER H WIN
- Type
- Physician · Allopathic & Osteopathic Physicians / Ophthalmology
- Where
- ARCADIA, CA
- NPI
- 1124040209
- Received
- $276,122 in 172 records, 2019 to 2025 ($2,854 general, $273,267 research)
- As principal investigator
- $4,154,135 of research payments to others in 1,314 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 16 | $396 |
| 2025 | Research payment | 3 | $11,800 |
| 2024 | General payment | 14 | $307 |
| 2024 | Research payment | 4 | $41,692 |
| 2023 | General payment | 23 | $529 |
| 2023 | Research payment | 6 | $95,996 |
| 2022 | General payment | 22 | $408 |
| 2022 | Research payment | 8 | $123,777 |
| 2021 | General payment | 31 | $467 |
| 2020 | General payment | 18 | $369 |
| 2019 | General payment | 27 | $376 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 21 | $273,267 |
| Food and Beverage | 147 | $2,753 |
| Gift | 4 | $101 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-27 | Regeneron Pharmaceuticals, Inc. | $431 | Research payment | In-kind items and services | EYLEA HD Biological, OPHTHALMOLOGY | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PA | 2025 |
| 2025-12-10 | Harrow Eye, LLC | $23 | Food and Beverage | In-kind items and services | VEVYE Drug, OPTOMETRY | 2025 | |
| 2025-10-15 | Harrow Eye, LLC | $30 | Food and Beverage | In-kind items and services | VEVYE Drug, OPTOMETRY | 2025 | |
| 2025-10-09 | Astellas Pharma US Inc | $31 | Food and Beverage | In-kind items and services | Izervay Drug, Ophthalmology | 2025 | |
| 2025-10-02 | SUN PHARMACEUTICAL INDUSTRIES INC. | $24 | Food and Beverage | In-kind items and services | Cequa Drug, Ophthalmology | 2025 | |
| 2025-08-27 | Alcon Vision LLC | $30 | Food and Beverage | In-kind items and services | Rocklatan Drug, Ophthalmology | 2025 | |
| 2025-08-01 | Genentech, Inc. | $2,725 | Research payment | Cash or cash equivalent | Faricimab for Under represented Patients with DME | 2025 | |
| 2025-07-30 | Alcon Vision LLC | $25 | Food and Beverage | In-kind items and services | TRYPTYR Drug, Ophthalmology | 2025 | |
| 2025-06-12 | SUN PHARMACEUTICAL INDUSTRIES INC. | $21 | Food and Beverage | In-kind items and services | Cequa Drug, Ophthalmology | 2025 | |
| 2025-04-25 | bioMerieux Inc | $19 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-04-17 | Harrow Eye, LLC | $22 | Food and Beverage | In-kind items and services | VEVYE Drug, OPTOMETRY | 2025 | |
| 2025-04-10 | SUN PHARMACEUTICAL INDUSTRIES INC. | $23 | Food and Beverage | In-kind items and services | Cequa Drug, Ophthalmology | 2025 | |
| 2025-04-09 | Alcon Vision LLC | $17 | Food and Beverage | In-kind items and services | Rocklatan Drug, Ophthalmology | 2025 | |
| 2025-03-12 | Harrow Eye, LLC | $28 | Food and Beverage | In-kind items and services | VEVYE Drug, OPTOMETRY | 2025 | |
| 2025-03-11 | Genentech, Inc. | $8,644 | Research payment | Cash or cash equivalent | Faricimab for Under represented Patients with DME | 2025 | |
| 2025-03-07 | SUN PHARMACEUTICAL INDUSTRIES INC. | $17 | Food and Beverage | In-kind items and services | Cequa Drug, Ophthalmology | 2025 | |
| 2025-02-14 | Alcon Vision LLC | $28 | Food and Beverage | In-kind items and services | Rocklatan Drug, Ophthalmology | 2025 | |
| 2025-02-07 | Bausch & Lomb Americas Inc. | $25 | Food and Beverage | In-kind items and services | XIIDRA Drug, Ophthalmology | 2025 | |
| 2025-02-06 | SUN PHARMACEUTICAL INDUSTRIES INC. | $28 | Food and Beverage | In-kind items and services | Cequa Drug, Ophthalmology | 2025 | |
| 2024-12-18 | Alcon Vision LLC | $23 | Food and Beverage | In-kind items and services | Rocklatan Drug, Ophthalmology | 2024 | |
| 2024-12-17 | Genentech, Inc. | $6,548 | Research payment | Cash or cash equivalent | Faricimab for Under represented Patients with DME | 2024 | |
| 2024-11-08 | Bausch & Lomb Americas Inc. | $23 | Food and Beverage | In-kind items and services | MIEBO Drug, Ophthalmology | 2024 | |
| 2024-10-24 | SUN PHARMACEUTICAL INDUSTRIES INC. | $27 | Food and Beverage | In-kind items and services | Cequa Drug, Ophthalmology | 2024 | |
| 2024-10-23 | Oyster Point Pharma, Inc. | $15 | Food and Beverage | In-kind items and services | TYRVAYA Drug, Dry eyes | 2024 | |
| 2024-10-05 | Bausch & Lomb Americas Inc. | $19 | Food and Beverage | In-kind items and services | VYZULTA Drug, Ophthalmology | 2024 | |
| 2024-09-18 | Tarsus Pharmaceuticals, Inc. | $26 | Food and Beverage | In-kind items and services | XDEMVY Drug, DEMODEX BLEPHARITIS | 2024 | |
| 2024-09-11 | SUN PHARMACEUTICAL INDUSTRIES INC. | $25 | Food and Beverage | In-kind items and services | Cequa Drug, Ophthalmology | 2024 | |
| 2024-07-22 | Bausch & Lomb Americas Inc. | $20 | Food and Beverage | In-kind items and services | XIIDRA Drug, Ophthalmology | 2024 | |
| 2024-06-25 | Genentech, Inc. | $17,190 | Research payment | Cash or cash equivalent | Faricimab for Under represented Patients with DME | 2024 | |
| 2024-05-23 | Oyster Point Pharma, Inc. | $18 | Food and Beverage | In-kind items and services | TYRVAYA Drug, Dry eyes | 2024 | |
| 2024-05-08 | Regeneron Healthcare Solutions, Inc. | $26 | Food and Beverage | In-kind items and services | EYLEA Biological, OPHTHALMOLOGY | 2024 | |
| 2024-05-02 | SUN PHARMACEUTICAL INDUSTRIES INC. | $20 | Food and Beverage | In-kind items and services | Cequa Drug, Ophthalmology | 2024 | |
| 2024-04-30 | Bausch & Lomb Americas Inc. | $16 | Food and Beverage | In-kind items and services | XIIDRA Drug, Ophthalmology | 2024 | |
| 2024-03-21 | Genentech, Inc. | $9,855 | Research payment | Cash or cash equivalent | Faricimab for Under represented Patients with DME | 2024 | |
| 2024-03-18 | Bausch & Lomb Americas Inc. | $21 | Food and Beverage | In-kind items and services | MIEBO Drug, Ophthalmology | 2024 | |
| 2024-01-25 | Hexal AG | $8,099 | Research payment | Cash or cash equivalent | CSOK583A12301 | 2024 | |
| 2024-01-18 | SUN PHARMACEUTICAL INDUSTRIES INC. | $22 | Food and Beverage | In-kind items and services | Cequa Drug, Ophthalmology | 2024 | |
| 2023-12-14 | Biogen, Inc. | $17 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-11-30 | Regeneron Healthcare Solutions, Inc. | $25 | Food and Beverage | In-kind items and services | EYLEA HD Biological, OPHTHALMOLOGY | 2023 | |
| 2023-10-26 | SUN PHARMACEUTICAL INDUSTRIES INC. | $33 | Food and Beverage | In-kind items and services | Cequa Drug, Ophthalmology | 2023 | |
| 2023-10-18 | SUN PHARMACEUTICAL INDUSTRIES INC. | $5 | Food and Beverage | In-kind items and services | Cequa Drug, Ophthalmology | 2023 | |
| 2023-10-16 | Bausch & Lomb Americas Inc. | $20 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-09-21 | SUN PHARMACEUTICAL INDUSTRIES INC. | $31 | Food and Beverage | In-kind items and services | Cequa Drug, Ophthalmology | 2023 | |
| 2023-08-29 | Bausch & Lomb Americas Inc. | $20 | Food and Beverage | In-kind items and services | PROLENSA Drug, Ophthalmology | 2023 | |
| 2023-08-22 | Genentech, Inc. | $12,194 | Research payment | Cash or cash equivalent | Faricimab for Under represented Patients with DME | 2023 | |
| 2023-08-03 | Novartis Pharmaceuticals Corporation | $27 | Food and Beverage | In-kind items and services | XIIDRA Drug, Ophthalmology | 2023 | |
| 2023-07-06 | Mallinckrodt Hospital Products Inc. | $25 | Food and Beverage | In-kind items and services | ACTHAR Biological, IMMUNOLOGY | 2023 | |
| 2023-07-05 | Genentech, Inc. | $19,133 | Research payment | Cash or cash equivalent | Faricimab for Under represented Patients with DME | 2023 | |
| 2023-06-30 | Genentech USA, Inc. | $23 | Food and Beverage | In-kind items and services | Vabysmo Drug, Immunology and Ophthalmology | 2023 | |
| 2023-06-22 | SUN PHARMACEUTICAL INDUSTRIES INC. | $23 | Food and Beverage | In-kind items and services | Cequa Drug, Ophthalmology | 2023 | |
| 2023-06-21 | Genentech USA, Inc. | $18 | Food and Beverage | In-kind items and services | Vabysmo Drug, Immunology and Ophthalmology | 2023 | |
| 2023-06-19 | Bausch & Lomb Americas Inc. | $21 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-06-15 | Apellis Pharmaceuticals, Inc. | $19 | Food and Beverage | Cash or cash equivalent | Syfovre Drug, Ophthalmology | 2023 | |
| 2023-06-08 | Novartis Pharmaceuticals Corporation | $30 | Food and Beverage | In-kind items and services | XIIDRA Drug, Ophthalmology | 2023 | |
| 2023-06-07 | SUN PHARMACEUTICAL INDUSTRIES INC. | $6 | Food and Beverage | In-kind items and services | Cequa Drug, Ophthalmology | 2023 | |
| 2023-05-11 | SUN PHARMACEUTICAL INDUSTRIES INC. | $21 | Food and Beverage | In-kind items and services | Cequa Drug, Ophthalmology | 2023 | |
| 2023-04-12 | Mallinckrodt Hospital Products Inc. | $29 | Food and Beverage | In-kind items and services | ACTHAR Biological, IMMUNOLOGY | 2023 | |
| 2023-04-12 | Novartis Pharmaceuticals Corporation | $24 | Food and Beverage | In-kind items and services | XIIDRA Drug, Ophthalmology | 2023 | |
| 2023-04-06 | Alcon Vision LLC | $17 | Food and Beverage | In-kind items and services | Rocklatan Drug, Ophthalmology | 2023 | |
| 2023-03-29 | SUN PHARMACEUTICAL INDUSTRIES INC. | $32 | Food and Beverage | In-kind items and services | Cequa Drug, Ophthalmology | 2023 | |
| 2023-03-01 | Genentech, Inc. | $935 | Research payment | Cash or cash equivalent | Faricimab for Under represented Patients with DME | 2023 | |
| 2023-02-16 | SUN PHARMACEUTICAL INDUSTRIES INC. | $26 | Food and Beverage | In-kind items and services | Cequa Drug, Ophthalmology | 2023 | |
| 2023-02-07 | Genentech, Inc. | $50,090 | Research payment | Cash or cash equivalent | Faricimab for Under represented Patients with DME | 2023 | |
| 2023-02-07 | Genentech, Inc. | $12,113 | Research payment | Cash or cash equivalent | Faricimab for Under represented Patients with DME | 2023 | |
| 2023-02-07 | Genentech, Inc. | $1,531 | Research payment | Cash or cash equivalent | Faricimab for Under represented Patients with DME | 2023 | |
| 2023-01-19 | SUN PHARMACEUTICAL INDUSTRIES INC. | $26 | Food and Beverage | In-kind items and services | Cequa Drug, Ophthalmology | 2023 | |
| 2022-12-19 | SUN PHARMACEUTICAL INDUSTRIES INC. | $24 | Food and Beverage | In-kind items and services | Cequa Drug, Ophthalmology | 2022 | |
| 2022-12-15 | Hexal AG | $11,229 | Research payment | Cash or cash equivalent | CSOK583A12301 | 2022 | |
| 2022-12-15 | Apellis Pharmaceuticals, Inc. | $22 | Food and Beverage | Cash or cash equivalent | 2022 | ||
| 2022-12-06 | Genentech, Inc. | $33,121 | Research payment | Cash or cash equivalent | VABYSMO Drug, Immunology and Ophthalmology | FARICIMAB FOR UNDER REPRESENTED PATIENTS WITH DME | 2022 |
| 2022-12-06 | Genentech, Inc. | $12,113 | Research payment | Cash or cash equivalent | VABYSMO Drug, Immunology and Ophthalmology | FARICIMAB FOR UNDER REPRESENTED PATIENTS WITH DME | 2022 |
| 2022-12-06 | Genentech, Inc. | $1,531 | Research payment | Cash or cash equivalent | VABYSMO Drug, Immunology and Ophthalmology | FARICIMAB FOR UNDER REPRESENTED PATIENTS WITH DME | 2022 |
| 2022-11-21 | Regeneron Healthcare Solutions, Inc. | $33 | Food and Beverage | In-kind items and services | EYLEA Biological, OPHTHALMOLOGY | 2022 | |
| 2022-11-01 | Genentech, Inc. | $12,011 | Research payment | Cash or cash equivalent | VABYSMO Drug, Immunology and Ophthalmology | FARICIMAB FOR UNDER REPRESENTED PATIENTS WITH DME | 2022 |
| 2022-10-10 | SUN PHARMACEUTICAL INDUSTRIES INC. | $23 | Food and Beverage | In-kind items and services | Cequa Drug, Ophthalmology | 2022 | |
| 2022-09-22 | Hexal AG | $2,215 | Research payment | Cash or cash equivalent | CSOK583A12301 | 2022 | |
| 2022-08-29 | Regeneron Healthcare Solutions, Inc. | $32 | Food and Beverage | In-kind items and services | EYLEA Biological, OPHTHALMOLOGY | 2022 | |
| 2022-08-29 | SUN PHARMACEUTICAL INDUSTRIES INC. | $5 | Food and Beverage | In-kind items and services | Cequa Drug, Ophthalmology | 2022 | |
| 2022-08-16 | Mallinckrodt Hospital Products Inc. | $18 | Food and Beverage | In-kind items and services | ACTHAR Biological, IMMUNOLOGY | 2022 | |
| 2022-08-08 | SUN PHARMACEUTICAL INDUSTRIES INC. | $25 | Food and Beverage | In-kind items and services | Cequa Drug, Ophthalmology | 2022 | |
| 2022-06-23 | Hexal AG | $31,475 | Research payment | Cash or cash equivalent | CSOK583A12301 | 2022 | |
| 2022-06-09 | SUN PHARMACEUTICAL INDUSTRIES INC. | $19 | Food and Beverage | In-kind items and services | Cequa Drug, Ophthalmology | 2022 | |
| 2022-06-08 | Bausch & Lomb Americas Inc. | $20 | Food and Beverage | In-kind items and services | PROLENSA Drug, Ophthalmology | 2022 | |
| 2022-05-26 | Mallinckrodt Hospital Products Inc. | $20 | Food and Beverage | In-kind items and services | ACTHAR Biological, IMMUNOLOGY | 2022 | |
| 2022-05-12 | Genentech USA, Inc. | $21 | Food and Beverage | In-kind items and services | SUSVIMO Drug, Immunology and Ophthalmology | 2022 | |
| 2022-05-06 | Spark Therapeutics, Inc. | $21 | Food and Beverage | In-kind items and services | LUXTURNA Biological, OCULAR | 2022 | |
| 2022-05-02 | Novartis Pharmaceuticals Corporation | $21 | Food and Beverage | In-kind items and services | XIIDRA Drug, OPHTHALMOLOGY | 2022 | |
| 2022-04-18 | Eyevance Pharmaceuticals LLC | $14 | Food and Beverage | In-kind items and services | Flarex Drug, OPHTHALMIC | 2022 | |
| 2022-04-07 | Genentech USA, Inc. | $21 | Food and Beverage | In-kind items and services | SUSVIMO Drug, Immunology and Ophthalmology | 2022 | |
| 2022-04-07 | SUN PHARMACEUTICAL INDUSTRIES INC. | $5 | Food and Beverage | In-kind items and services | Cequa Drug, Ophthalmology | 2022 | |
| 2022-03-17 | Hexal AG | $20,080 | Research payment | Cash or cash equivalent | CSOK583A12301 | 2022 | |
| 2022-03-17 | Alimera Sciences, Inc. | $11 | Food and Beverage | Cash or cash equivalent | ILUVIEN Drug, OPHTHALMOLOGY | 2022 | |
| 2022-03-10 | SUN PHARMACEUTICAL INDUSTRIES INC. | $5 | Food and Beverage | In-kind items and services | Cequa Drug, Ophthalmology | 2022 | |
| 2022-02-17 | SUN PHARMACEUTICAL INDUSTRIES INC. | $15 | Food and Beverage | In-kind items and services | Cequa Drug, Ophthalmology | 2022 | |
| 2022-02-08 | Alcon Vision LLC | $18 | Food and Beverage | In-kind items and services | Simbrinza Drug, Ophthalmology | 2022 | |
| 2022-01-27 | SUN PHARMACEUTICAL INDUSTRIES INC. | $5 | Food and Beverage | In-kind items and services | Cequa Drug, Ophthalmology | 2022 | |
| 2021-12-14 | Mallinckrodt Hospital Products Inc. | $29 | Food and Beverage | In-kind items and services | ACTHAR Biological, IMMUNOLOGY | 2021 | |
| 2021-12-11 | Mallinckrodt Hospital Products Inc. | $24 | Food and Beverage | In-kind items and services | ACTHAR Biological, IMMUNOLOGY | 2021 | |
| 2021-12-06 | SUN PHARMACEUTICAL INDUSTRIES INC. | $20 | Food and Beverage | In-kind items and services | Cequa Drug, Ophthalmology | 2021 | |
| 2021-11-29 | SUN PHARMACEUTICAL INDUSTRIES INC. | $12 | Food and Beverage | In-kind items and services | Cequa Drug, Ophthalmology | 2021 | |
| 2021-10-25 | Alimera Sciences, Inc. | $14 | Food and Beverage | Cash or cash equivalent | ILUVIEN Drug, OPHTHALMOLOGY | 2021 | |
| 2021-10-12 | Allergan, Inc. | $14 | Food and Beverage | In-kind items and services | RESTASIS MULTIDOSE Drug, DRY EYE | 2021 | |
| 2021-10-05 | SUN PHARMACEUTICAL INDUSTRIES INC. | $23 | Food and Beverage | In-kind items and services | Cequa Drug, Ophthalmology | 2021 | |
| 2021-09-27 | SUN PHARMACEUTICAL INDUSTRIES INC. | $4 | Food and Beverage | In-kind items and services | Cequa Drug, Ophthalmology | 2021 | |
| 2021-09-20 | Eyevance Pharmaceuticals LLC | $13 | Food and Beverage | In-kind items and services | Zerviate Drug, ophthalmic | 2021 | |
| 2021-09-17 | Aerie Pharmaceuticals, Inc. | $17 | Food and Beverage | In-kind items and services | rhopressa Drug, Glaucoma | 2021 | |
| 2021-09-13 | SUN PHARMACEUTICAL INDUSTRIES INC. | $4 | Food and Beverage | In-kind items and services | Cequa Drug, Ophthalmology | 2021 | |
| 2021-09-02 | SUN PHARMACEUTICAL INDUSTRIES INC. | $21 | Food and Beverage | In-kind items and services | Cequa Drug, Ophthalmology | 2021 | |
| 2021-08-23 | Novartis Pharmaceuticals Corporation | $17 | Food and Beverage | In-kind items and services | XIIDRA Drug, OPHTHALMOLOGY | 2021 | |
| 2021-07-26 | Aerie Pharmaceuticals, Inc. | $18 | Food and Beverage | In-kind items and services | rocklatan Drug, Glaucoma | 2021 | |
| 2021-07-26 | SUN PHARMACEUTICAL INDUSTRIES INC. | $4 | Food and Beverage | In-kind items and services | Cequa Drug, Ophthalmology | 2021 | |
| 2021-06-28 | Regeneron Healthcare Solutions, Inc. | $25 | Food and Beverage | In-kind items and services | EYLEA Biological, OPHTHALMOLOGY | 2021 | |
| 2021-06-07 | SUN PHARMACEUTICAL INDUSTRIES INC. | $3 | Food and Beverage | In-kind items and services | Cequa Drug, Ophthalmology | 2021 | |
| 2021-05-24 | SUN PHARMACEUTICAL INDUSTRIES INC. | $15 | Food and Beverage | In-kind items and services | Cequa Drug, Ophthalmology | 2021 | |
| 2021-05-12 | Mallinckrodt Hospital Products Inc. | $25 | Food and Beverage | In-kind items and services | ACTHAR Biological, IMMUNOLOGY | 2021 | |
| 2021-05-10 | Novartis Pharmaceuticals Corporation | $17 | Food and Beverage | In-kind items and services | XIIDRA Drug, OPHTHALMOLOGY | 2021 | |
| 2021-05-04 | Mallinckrodt Hospital Products Inc. | $22 | Food and Beverage | In-kind items and services | ACTHAR Biological, IMMUNOLOGY | 2021 | |
| 2021-04-19 | SUN PHARMACEUTICAL INDUSTRIES INC. | $16 | Food and Beverage | In-kind items and services | Cequa Drug, Ophthalmology | 2021 | |
| 2021-04-19 | Bausch & Lomb, a division of Bausch Health US, LLC | $14 | Food and Beverage | In-kind items and services | PROLENSA Drug, Ophthalmology | 2021 | |
| 2021-03-16 | Allergan, Inc. | $13 | Food and Beverage | In-kind items and services | COMBIGAN Drug, OPHTHALMOLOGY | 2021 | |
| 2021-03-01 | Bausch & Lomb, a division of Bausch Health US, LLC | $14 | Food and Beverage | In-kind items and services | PROLENSA Drug, Ophthalmology | 2021 | |
| 2021-02-18 | SUN PHARMACEUTICAL INDUSTRIES INC. | $7 | Food and Beverage | In-kind items and services | Cequa Drug, Ophthalmology | 2021 | |
| 2021-02-09 | Allergan, Inc. | $12 | Food and Beverage | In-kind items and services | RESTASIS MULTIDOSE Drug, DRY EYE | 2021 | |
| 2021-02-03 | Aerie Pharmaceuticals, Inc. | $11 | Food and Beverage | In-kind items and services | rocklatan Drug, Glaucoma | 2021 | |
| 2021-01-28 | SUN PHARMACEUTICAL INDUSTRIES INC. | $8 | Food and Beverage | In-kind items and services | Cequa Drug, Ophthalmology | 2021 | |
| 2021-01-21 | SUN PHARMACEUTICAL INDUSTRIES INC. | $9 | Food and Beverage | In-kind items and services | Cequa Drug, Ophthalmology | 2021 | |
| 2021-01-13 | SUN PHARMACEUTICAL INDUSTRIES INC. | $8 | Food and Beverage | In-kind items and services | Cequa Drug, Ophthalmology | 2021 | |
| 2020-12-17 | SUN PHARMACEUTICAL INDUSTRIES INC. | $23 | Food and Beverage | Cash or cash equivalent | XELPROS Drug, Ophthalmology | 2020 | |
| 2020-12-04 | SUN PHARMACEUTICAL INDUSTRIES INC. | $22 | Food and Beverage | Cash or cash equivalent | XELPROS Drug, Ophthalmology | 2020 | |
| 2020-11-24 | Bausch & Lomb, a division of Bausch Health US, LLC | $13 | Food and Beverage | In-kind items and services | PROLENSA Drug, OPHTHALMOLOGY | 2020 | |
| 2020-11-10 | Allergan, Inc. | $13 | Food and Beverage | In-kind items and services | COMBIGAN Drug, OPHTHALMOLOGY | 2020 | |
| 2020-11-05 | Aerie Pharmaceuticals, Inc. | $21 | Food and Beverage | In-kind items and services | rhopressa Drug, Glaucoma | 2020 | |
| 2020-10-06 | Allergan, Inc. | $13 | Food and Beverage | In-kind items and services | OZURDEX Drug, RETINA | 2020 | |
| 2020-09-17 | Allergan, Inc. | $22 | Food and Beverage | In-kind items and services | RESTASIS Drug, DRY EYE | 2020 | |
| 2020-08-24 | Bausch & Lomb, a division of Bausch Health US, LLC | $13 | Food and Beverage | In-kind items and services | PROLENSA Drug, OPHTHALMOLOGY | 2020 | |
| 2020-08-08 | Bausch & Lomb, a division of Bausch Health US, LLC | $12 | Food and Beverage | In-kind items and services | PROLENSA Drug, OPHTHALMOLOGY | 2020 | |
| 2020-08-06 | SUN PHARMACEUTICAL INDUSTRIES INC. | $21 | Food and Beverage | Cash or cash equivalent | XELPROS Drug, Ophthalmology | 2020 | |
| 2020-08-03 | Allergan, Inc. | $45 | Gift | In-kind items and services | DURYSTA Drug, GLAUCOMA | 2020 | |
| 2020-08-03 | Aerie Pharmaceuticals, Inc. | $24 | Food and Beverage | In-kind items and services | rhopressa Drug, Glaucoma | 2020 | |
| 2020-06-15 | SUN PHARMACEUTICAL INDUSTRIES INC. | $20 | Food and Beverage | Cash or cash equivalent | BROMSITE Drug, Ophthalmology | 2020 | |
| 2020-05-13 | Carl Zeiss Meditec, Inc. | $17 | Gift | In-kind items and services | None Specified Medical Supply | 2020 | |
| 2020-05-08 | Carl Zeiss Meditec AG | $19 | Gift | In-kind items and services | None Specified Medical Supply | 2020 | |
| 2020-05-08 | Carl Zeiss Meditec AG | $19 | Gift | In-kind items and services | None Specified Medical Supply | 2020 | |
| 2020-02-19 | Aerie Pharmaceuticals, Inc. | $24 | Food and Beverage | In-kind items and services | rhopressa Drug, Glaucoma | 2020 | |
| 2020-01-27 | Allergan, Inc. | $19 | Food and Beverage | In-kind items and services | OZURDEX Drug, RETINA | 2020 | |
| 2019-12-16 | Allergan, Inc. | $19 | Food and Beverage | In-kind items and services | OZURDEX Drug, RETINA | 2019 | |
| 2019-12-09 | Eyevance Pharmaceuticals LLC | $18 | Food and Beverage | In-kind items and services | Flarex Drug, Ophthalmology | 2019 | |
| 2019-12-02 | Aerie Pharmaceuticals, Inc. | $24 | Food and Beverage | In-kind items and services | Rhopressa Drug, Glaucoma | 2019 | |
| 2019-10-30 | SUN PHARMACEUTICAL INDUSTRIES INC. | $22 | Food and Beverage | Cash or cash equivalent | BROMSITE Drug, Ophthalmology | 2019 | |
| 2019-10-30 | Horizon Therapeutics plc | $18 | Food and Beverage | In-kind items and services | 2019 | ||
| 2019-10-15 | Bausch & Lomb, a division of Bausch Health US, LLC | $11 | Food and Beverage | In-kind items and services | PROLENSA Drug, OPHTHALMOLOGY | 2019 | |
| 2019-10-03 | Novartis Pharmaceuticals Corporation | $8 | Food and Beverage | In-kind items and services | XIIDRA Drug, OPHTHALMOLOGY | 2019 | |
| 2019-09-13 | SUN PHARMACEUTICAL INDUSTRIES INC. | $13 | Food and Beverage | Cash or cash equivalent | XELPROS Drug, Ophthalmology | 2019 | |
| 2019-08-22 | Novartis Pharmaceuticals Corporation | $24 | Food and Beverage | In-kind items and services | 2019 | ||
| 2019-08-14 | Novartis Pharmaceuticals Corporation | $4 | Food and Beverage | In-kind items and services | DUREZOL Drug, OPHTHALMOLOGY | 2019 | |
| 2019-08-07 | Allergan, Inc. | $22 | Food and Beverage | In-kind items and services | OZURDEX Drug, RETINA | 2019 | |
| 2019-08-07 | Novartis Pharmaceuticals Corporation | $18 | Food and Beverage | In-kind items and services | DUREZOL Drug, OPHTHALMOLOGY | 2019 | |
| 2019-07-10 | Novartis Pharmaceuticals Corporation | $14 | Food and Beverage | In-kind items and services | DUREZOL Drug, OPHTHALMOLOGY | 2019 | |
| 2019-06-27 | Novartis Pharmaceuticals Corporation | $3 | Food and Beverage | In-kind items and services | DUREZOL Drug, OPHTHALMOLOGY | 2019 | |
| 2019-06-20 | Novartis Pharmaceuticals Corporation | $23 | Food and Beverage | In-kind items and services | DUREZOL Drug, OPHTHALMOLOGY | 2019 | |
| 2019-06-12 | Novartis Pharmaceuticals Corporation | $3 | Food and Beverage | In-kind items and services | DUREZOL Drug, OPHTHALMOLOGY | 2019 | |
| 2019-06-06 | Novartis Pharmaceuticals Corporation | $23 | Food and Beverage | In-kind items and services | 2019 | ||
| 2019-05-29 | Kala Pharmaceuticals, Inc. | $15 | Food and Beverage | In-kind items and services | INVELTYS Drug, OCULAR | 2019 | |
| 2019-05-22 | Novartis Pharmaceuticals Corporation | $6 | Food and Beverage | In-kind items and services | DUREZOL Drug, OPHTHALMOLOGY | 2019 | |
| 2019-04-17 | Novartis Pharmaceuticals Corporation | $1 | Food and Beverage | In-kind items and services | DUREZOL Drug, OPHTHALMOLOGY | 2019 | |
| 2019-04-03 | Novartis Pharmaceuticals Corporation | $5 | Food and Beverage | In-kind items and services | DUREZOL Drug, OPHTHALMOLOGY | 2019 | |
| 2019-03-14 | Eyevance Pharmaceuticals LLC | $13 | Food and Beverage | In-kind items and services | Flarex Drug, Ophthalmology | 2019 | |
| 2019-03-13 | Novartis Pharmaceuticals Corporation | $1 | Food and Beverage | In-kind items and services | DUREZOL Drug, OPHTHALMOLOGY | 2019 | |
| 2019-02-18 | Alimera Sciences, Inc. | $9 | Food and Beverage | Cash or cash equivalent | Iluvien Drug, Ophthalmology | 2019 | |
| 2019-02-06 | Novartis Pharmaceuticals Corporation | $3 | Food and Beverage | In-kind items and services | DUREZOL Drug, OPHTHALMOLOGY | 2019 | |
| 2019-02-04 | EyePoint Pharmaceuticals US, Inc. | $17 | Food and Beverage | In-kind items and services | YUTIQ Drug, Chronic Non-infectious Posterior Segment Uveitis | 2019 | |
| 2019-01-15 | SUN PHARMACEUTICAL INDUSTRIES INC. | $23 | Food and Beverage | Cash or cash equivalent | BROMSITE Drug, Ophthalmology | 2019 |
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-31 | Boehringer Ingelheim International GmbH | Win Retina-Arcadia | $40 | A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI181536 | 2025 |
| 2025-12-19 | KYOWA KIRIN, INC. | WIN RETINA | $1,958 | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 |
| 2025-12-19 | KYOWA KIRIN, INC. | WIN RETINA | $1,958 | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 |
| 2025-12-19 | KYOWA KIRIN, INC. | WIN RETINA | $1,161 | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 |
| 2025-12-19 | KYOWA KIRIN, INC. | WIN RETINA | $2,000 | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 |
| 2025-12-19 | KYOWA KIRIN, INC. | WIN RETINA | $4,688 | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 |
| 2025-12-12 | KYOWA KIRIN, INC. | WIN RETINA | $2,865 | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 |
| 2025-12-12 | KYOWA KIRIN, INC. | WIN RETINA | $2,277 | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 |
| 2025-12-12 | KYOWA KIRIN, INC. | WIN RETINA | $2,677 | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 |
| 2025-12-12 | KYOWA KIRIN, INC. | WIN RETINA | $1,956 | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 |
| 2025-12-12 | KYOWA KIRIN, INC. | WIN RETINA | $2,865 | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 |
| 2025-12-12 | KYOWA KIRIN, INC. | WIN RETINA | $4,476 | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 |
| 2025-12-12 | KYOWA KIRIN, INC. | WIN RETINA | $5,586 | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $2,554 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $2,554 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $2,554 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $2,554 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $2,554 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $1,393 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $2,554 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $2,554 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $2,554 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $2,554 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $2,554 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $2,554 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $2,554 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $2,554 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $2,554 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $2,554 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $2,554 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $2,554 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $2,554 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $2,554 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $2,554 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $2,554 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $2,554 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $2,554 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $2,554 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $2,554 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $2,554 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $2,554 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $2,554 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $2,554 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $2,554 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $2,554 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $2,554 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $1,393 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $2,554 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $2,554 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $2,554 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $1,393 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $2,554 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $2,554 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $2,554 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-11-28 | KYOWA KIRIN, INC. | WIN RETINA | $695 | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 |
| 2025-11-28 | KYOWA KIRIN, INC. | WIN RETINA | $250 | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 |
| 2025-11-27 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $1,950 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-11-27 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $1,200 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-11-27 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $1,000 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-11-27 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $7,000 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-11-27 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $2,000 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-11-17 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $2,013 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-11-17 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $2,013 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-10-31 | Boehringer Ingelheim International GmbH | Win Retina-Arcadia | $40 | A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI181536 | 2025 |
| 2025-10-30 | KYOWA KIRIN, INC. | WIN RETINA | $39,358 | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 |
| 2025-10-28 | Boehringer Ingelheim International GmbH | Win Retina-Arcadia | $40 | A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI181536 | 2025 |
| 2025-10-27 | KYOWA KIRIN, INC. | WIN RETINA | $1,956 | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 |
| 2025-10-27 | KYOWA KIRIN, INC. | WIN RETINA | $2,677 | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 |
| 2025-10-27 | KYOWA KIRIN, INC. | WIN RETINA | $3,800 | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 |
| 2025-10-27 | KYOWA KIRIN, INC. | WIN RETINA | $2,677 | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 |
| 2025-10-27 | KYOWA KIRIN, INC. | WIN RETINA | $2,865 | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 |
| 2025-10-27 | KYOWA KIRIN, INC. | WIN RETINA | $2,277 | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 |
| 2025-10-27 | KYOWA KIRIN, INC. | WIN RETINA | $1,956 | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 |
| 2025-10-27 | KYOWA KIRIN, INC. | WIN RETINA | $1,161 | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 |
| 2025-10-27 | KYOWA KIRIN, INC. | WIN RETINA | $2,677 | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 |
| 2025-10-27 | KYOWA KIRIN, INC. | WIN RETINA | $1,161 | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 |
| 2025-10-27 | KYOWA KIRIN, INC. | WIN RETINA | $1,161 | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 |
| 2025-10-27 | KYOWA KIRIN, INC. | WIN RETINA | $5,560 | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 |
| 2025-10-27 | KYOWA KIRIN, INC. | WIN RETINA | $1,161 | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 |
| 2025-10-27 | KYOWA KIRIN, INC. | WIN RETINA | $2,677 | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 |
| 2025-10-27 | KYOWA KIRIN, INC. | WIN RETINA | $4,476 | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 |
| 2025-10-27 | KYOWA KIRIN, INC. | WIN RETINA | $2,845 | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 |
| 2025-10-03 | KYOWA KIRIN, INC. | WIN RETINA | $1,958 | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 |
| 2025-10-03 | KYOWA KIRIN, INC. | WIN RETINA | $4,104 | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 |
| 2025-10-03 | KYOWA KIRIN, INC. | WIN RETINA | $4,104 | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 |
| 2025-10-03 | KYOWA KIRIN, INC. | WIN RETINA | $5,586 | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A | 2025 |
| 2025-09-30 | Boehringer Ingelheim International GmbH | Win Retina-Arcadia | $40 | A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI181536 | 2025 |
| 2025-09-17 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $2,526 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-09-17 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $2,526 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-09-17 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $2,526 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-09-17 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $2,526 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-09-17 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $3,105 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-09-17 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $2,526 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-09-17 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $2,526 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-09-17 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $3,105 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-09-17 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $2,526 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-09-17 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $2,526 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-09-17 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $2,526 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-09-17 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $2,526 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
| 2025-09-17 | Regeneron Pharmaceuticals, Inc. | WIN RETINA | $2,526 | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | 2025 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Arcadia, CA, county Los Angeles County, CA, state California; placed by its city name.
| Measure | Place (city or town) Arcadia, CA | County Los Angeles County, CA | State California |
|---|---|---|---|
| Population B01003 | 55,170 | 9,808,667 | 39,287,377 |
| Population, 2020 census P1 | 56,681 | 10,014,009 | 39,538,223 |
| Median age B01002 | 43.9 | 38.2 | 37.9 |
| Under 18 B01001 | 20.9% | 20.6% | 22.0% |
| 65 and over B01001 | 20.6% | 15.2% | 15.7% |
| Households B11001 | 19,227 | 3,416,449 | 13,548,091 |
| Foreign born B05002 | 46.2% | 33.4% | 27.0% |
| Median household income B19013 | $113,516 | $90,112 | $99,122 |
| Median family income B19113 | $130,550 | $101,573 | $113,346 |
| Per capita income B19301 | $57,549 | $45,792 | $49,513 |
| Poverty rate B17001 | 8.6% | 13.7% | 12.0% |
| Unemployment rate B23025 | 5.7% | 7.3% | 6.6% |
| Civilian labor force B23025 | 26,225 | 5,200,656 | 20,068,466 |
| Mean commute (minutes) B08013 | 29.3 | 30.4 | 28.7 |
| Bachelor's degree or higher B15003 | 57.4% | 36.0% | 37.1% |
| Housing units B25001 | 20,992 | 3,650,466 | 14,644,735 |
| Owner-occupied B25003 | 58.1% | 45.9% | 55.9% |
| Renters B25003 | 41.9% | 54.1% | 44.1% |
| Median home value B25077 | $1,441,800 | $834,200 | $734,700 |
| Median gross rent B25064 | $2,191 | $1,954 | $2,036 |
| White, not Hispanic B03002 | 16.7% | 24.7% | 33.8% |
| Black B03002 | 1.6% | 7.4% | 5.2% |
| Hispanic or Latino B03002 | 17.5% | 48.4% | 40.2% |
| Asian B03002 | 58.7% | 14.9% | 15.3% |
| American Indian and Alaska Native B03002 | 0.5% | 0.2% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Arcadia, CA.
Comments